References
- Romero R, Erez O, Hüttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017;217(3):282–302. DOI:10.1016/j.ajog.2017.06.003.
- Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY). 2012;4(5):320–329.
- Anisimov VN. Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget. 2015;6(37):39398–39407.
- Barzilai N, Crandall JP, Kritchevsky SB, et al. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060–1065.
- Duca FA, Côté CD, Rasmussen BA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nature Med. 2015;21(5):506–511.
- Lee CK, Choi YJ, Park SY, et al. Intracerebroventricular injection of metformin induces anorexia in rats. Diabetes Metab J. 2012;36(4):293–299. DOI:10.4093/dmj.2012.36.4.293.
- Zhao P, Sui BD, Liu N, et al. Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application. Aging Cell. 2017;16(5):1083–1093.
- Wu CL, Qiang L, Han W, et al. Role of AMPK in UVB-induced DNA damage repair and growth control. Oncogene. 2013;32(21):2682–2689.
- Ochoa-Gonzalez F, Cervantes-Villagrana AR, Fernandez-Ruiz JC, et al. Metformin induces cell cycle arrest, reduced proliferation, wound healing impairment in vivo and is associated to clinical outcomes in diabetic foot ulcer patients. PLoS One. 2016;11(3):e0150900.
- Pradeep AR, Rao NS, Naik SB, et al. Efficacy of varying concentrations of subgingivally delivered metformin in the treatment of chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013;84(2):212–220.
- Lin HC, Stein JD, Nan B, et al. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 2015;133(8):915–923.
- Lee SY, Lee SH, Yang EJ, et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/Treg balance. PLoS One. 2015;10(9):e0135858.
- Nurani M, Akbari V, Taheri A. Preparation and characterization of metformin surface modified cellulose nanofiber gel and evaluation of its anti-metastatic potentials. Carbohydr Polym. 2017;165:322–333. DOI:10.1016/j.carbpol.2017.02.067.
- Zaghloul AA, Lila A, Abd-Allah F, et al. Preparation and in vitro/in vivo evaluation of metformin hydrochloride rectal dosage forms for treatment of patients with type II diabetes. J Drug Target. 2017;25(5):463–470.
- Wu X, He C, Wu Y, et al. Synergistic therapeutic effects of Schiff’s base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model. Biomaterials. 2016;75:148–162.
- Yang Q, Zhang T, Wang C, et al. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells. Eur J Pharm Biopharm. 2014;88(3):737–745.
- Menendez JA, Quirantes-Piné R, Rodríguez-Gallego E, et al. Oncobiguanides: paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget. 2014;5(9):2344–2348.
- Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA. 2013;110(3):972–977.
- Peng M, Su Q, Zeng Q, et al. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget. 2016;7(8):9102–9117.
- Neugut AI, Zhong X, Wright JD, et al. Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol. 2016;2(10):1326–1332.